{
  "Disease": [
    {"role": "user", "content": "Please identify the \"Disease\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Disease\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: The antipsychotic agent , remoxipride [ ( S ) - ( - ) - 3 - bromo - N - [ ( 1 - ethyl - 2 - pyrrolidinyl ) methyl ] - 2 , 6 - dimethoxybenz amide ] has been associated with acquired aplastic anemia .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| acquired aplastic anemia |"},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Disease\" and present the valid entities as a Markdown table with one column \"Disease\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| acquired aplastic anemia |"}
  ],
  "Chemical": [
    {"role": "user", "content": "Please identify the \"Chemical\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Chemical\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: The antipsychotic agent , remoxipride [ ( S ) - ( - ) - 3 - bromo - N - [ ( 1 - ethyl - 2 - pyrrolidinyl ) methyl ] - 2 , 6 - dimethoxybenz amide ] has been associated with acquired aplastic anemia .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| (S) - (--)-3-bromo-N-[ (1-ethyl-2-pyrrolidinyl) methyl ]-2,6-dimethoxybenzamide |\n| remoxipride |\n| (S) - 3-bromo-N-[ (1-ethyl-2-pyrrolidinyl) methyl ]-2,6-dimethoxybenzamide (structure name) |\n| 3-bromo-N-[ (1-ethyl-2-pyrrolidinyl) methyl ]-2,6-dimethoxybenzamide (IUPAC name) |\n| bromobenzamide, 3-[2,6-dimethoxy-1-(1-ethyl-2-pyrrolidinyl)methyl]- (S)- (--)- (IUPAC name for the chiral center) |\n| 2,6-dimethoxybenzamide, N-[1-ethyl-2-pyrrolidinylmethyl]-3-bromo- (IUPAC name for the functional groups) |\n\nNote: The parentheses and dashes in the IUPAC names are added to indicate the absolute configuration and the chiral center, respectively. The structure name and the common name (remoxipride) are provided for clarity and are not strictly IUPAC names."},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Chemical\" and present the valid entities as a Markdown table with one column \"Chemical\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| (S) - (--)-3-bromo-N-[ (1-ethyl-2-pyrrolidinyl) methyl ]-2,6-dimethoxybenzamide |\n| remoxipride |\n\nThe other entities in the paragraph do not clearly refer to chemicals, but rather to the specific structure or names of the chemical entity mentioned. Therefore, they are not included in the table."}
  ]
}